LFA Lugano Financial Advisors SA increased its stake in shares of CVS Health Corp (NYSE:CVS) by 48.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,090 shares of the pharmacy operator’s stock after acquiring an additional 1,341 shares during the period. LFA Lugano Financial Advisors SA’s holdings in CVS Health were worth $322,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in CVS Health in the 1st quarter valued at $103,000. GSA Capital Partners LLP raised its position in CVS Health by 641.3% in the 1st quarter. GSA Capital Partners LLP now owns 48,375 shares of the pharmacy operator’s stock valued at $3,009,000 after purchasing an additional 41,849 shares during the last quarter. M&R Capital Management Inc. raised its position in CVS Health by 3.6% in the 1st quarter. M&R Capital Management Inc. now owns 63,592 shares of the pharmacy operator’s stock valued at $3,960,000 after purchasing an additional 2,238 shares during the last quarter. Mcdaniel Terry & Co. raised its position in CVS Health by 2.2% in the 1st quarter. Mcdaniel Terry & Co. now owns 139,697 shares of the pharmacy operator’s stock valued at $8,691,000 after purchasing an additional 3,032 shares during the last quarter. Finally, Bristol John W & Co. Inc. NY bought a new position in CVS Health in the 1st quarter valued at $333,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

NYSE CVS opened at $74.58 on Friday. The firm has a market capitalization of $80.14 billion, a PE ratio of 12.64, a PEG ratio of 1.05 and a beta of 1.02. CVS Health Corp has a 52 week low of $60.14 and a 52 week high of $83.88. The company has a quick ratio of 1.87, a current ratio of 2.34 and a debt-to-equity ratio of 1.73.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 8th. The pharmacy operator reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.08. CVS Health had a return on equity of 18.25% and a net margin of 1.61%. The business had revenue of $46.71 billion during the quarter, compared to analysts’ expectations of $46.34 billion. During the same period in the previous year, the firm earned $1.33 earnings per share. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. As a group, equities research analysts expect that CVS Health Corp will post 7.05 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Wednesday, October 24th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.68%. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.

In related news, EVP Lisa Bisaccia sold 21,534 shares of CVS Health stock in a transaction on Monday, October 1st. The stock was sold at an average price of $80.00, for a total transaction of $1,722,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin Hourican sold 8,564 shares of CVS Health stock in a transaction on Monday, August 27th. The stock was sold at an average price of $75.00, for a total value of $642,300.00. Following the sale, the executive vice president now directly owns 12,135 shares of the company’s stock, valued at $910,125. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,409 shares of company stock valued at $3,392,097. 0.53% of the stock is owned by insiders.

Several equities research analysts have recently commented on CVS shares. Leerink Swann set a $80.00 target price on CVS Health and gave the company an “outperform” rating in a research note on Thursday, August 9th. Citigroup reissued a “buy” rating and issued a $81.00 target price on shares of CVS Health in a research note on Monday, July 9th. ValuEngine cut CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 4th. Morgan Stanley lowered their target price on CVS Health from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, July 3rd. Finally, Royal Bank of Canada lowered their target price on CVS Health to $84.00 and set an “outperform” rating for the company in a research note on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $86.31.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Featured Article: What is the yield curve?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.